$1.40
-0.01 (-0.71%)
Open$1.48
Previous Close$1.41
Day High$1.48
Day Low$1.35
52W High$35.00
52W Low$1.26
Volume—
Avg Volume71.5K
Market Cap3.14M
P/E Ratio—
EPS$-28.59
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,090.7% upside
Current
$1.40
$1.40
Target
$16.67
$16.67
$13.69
$16.67 avg
$25.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 42.68M | 586.6K | 551.3K |
| Net Income | -269,757,289 | -23,280 | -22,798 |
| Profit Margin | -632.0% | -4.0% | -4.1% |
| EBITDA | -270,368,438 | -32,929 | -31,435 |
| Free Cash Flow | — | -20,426 | -16,844 |
| Rev Growth | +117.3% | +23.9% | +11.9% |
| Debt/Equity | — | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |